{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:08:00Z","timestamp":1791299280451,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To report long-term treatment outcomes of intravitreal bevacizumab in myopic macular neovascularization (MNV).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective analysis of longitudinal, clinical data of patients with high myopic MNV treated with intravitreal bevacizumab. One-hundred and seventeen eyes of 106 patients were followed from first injection up to 12 years. Outcome measures were best-corrected visual acuity change during follow-up and myopic MNV recurrence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Mean (\u00b1SD) baseline best-corrected visual acuity (0.56 \u00b1 0.46 logMAR, 20\/80) significantly improved after first treatment (0.33 \u00b1 0.33, 20\/50, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). At 4 years (n = 86), best-corrected visual acuity was no longer significantly better than at baseline (0.55 \u00b1 0.57, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.30) and continued to deteriorate to 0.84 \u00b1 0.76 (20\/125) at 10 years (n = 27). Of the 27 eyes (23%) who reached 10 years of follow-up, 53% developed MNV-related chorioretinal atrophy. The cumulative incidence of recurrent myopic MNV was 34% at 2 years and 59% at 5 years. Best-corrected visual acuity decrease in eyes with or without recurrent MNV was similar (<jats:italic toggle=\"yes\">P =<\/jats:italic> 0.58). Patchy chorioretinal atrophy (hazard ratio 3.0, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02) and subfoveal MNVs (hazard ratio 2.5, <jats:italic toggle=\"yes\">P =<\/jats:italic> 0.048) were significantly associated with recurrent MNV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This retrospective myopic MNV study revealed that visual improvement after intravitreal bevacizumab injections was not maintained over time. Macular neovascularization recurrences occurred frequently but did not alter the already poor visual prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003675","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T21:00:32Z","timestamp":1668718832000},"page":"444-453","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["LONG-TERM TREATMENT OUTCOMES AFTER BEVACIZUMAB THERAPY FOR MACULAR NEOVASCULARIZATION IN WHITE PATIENTS WITH HIGH MYOPIA"],"prefix":"10.1097","volume":"43","author":[{"given":"Monica","family":"Ravenstijn","sequence":"first","affiliation":[{"name":"Rotterdam Ophthalmic Institute, Rotterdam Eye Hospital, Rotterdam, The Netherlands;"},{"name":"Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline C. W.","family":"Klaver","sequence":"additional","affiliation":[{"name":"Rotterdam Ophthalmic Institute, Rotterdam Eye Hospital, Rotterdam, The Netherlands;"},{"name":"Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands;"},{"name":"Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands; and"},{"name":"Institute of Molecular and Clinical Ophthalmology, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Yzer","sequence":"additional","affiliation":[{"name":"Rotterdam Ophthalmic Institute, Rotterdam Eye Hospital, Rotterdam, The Netherlands;"},{"name":"Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: the 12-month results from the repair study","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/IAE.0000000000001313","article-title":"Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia","volume":"37","author":"Kasahara","year":"2017","journal-title":"Retina"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjophthalmol-2017-310411","article-title":"Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group","volume":"102","author":"Chhablani","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1097\/IAE.0000000000000632","article-title":"Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia six years outcome","volume":"35","author":"Ruiz-Moreno","year":"2015","journal-title":"Retina"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00417-015-3076-1","article-title":"Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes","volume":"254","author":"Sarao","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/ph14101042","article-title":"Ten-year outcomes of intravitreal bevacizumab for myopic choroidal neovascularization: analysis of prognostic factors","volume":"14","author":"Mallone","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/IAE.0000000000002164","article-title":"Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia","volume":"39","author":"Onishi","year":"2019","journal-title":"Retina"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000446027","article-title":"Ranibizumab in myopic choroidal neovascularization: a subgroup Analysis by ethnicity, age, and ocular characteristics in RADIANCE","volume":"236","author":"Holz","year":"2016","journal-title":"Ophthalmologica"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1167\/iovs.12-11542","article-title":"Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization","volume":"54","author":"Ahn","year":"2013","journal-title":"Invest Opthalmol Vis Sci"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/IAE.0b013e3182278bae","article-title":"Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia","volume":"32","author":"Hayashi","year":"2012","journal-title":"Retina"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/IAE.0b013e31821ba2dc","article-title":"Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization","volume":"31","author":"Kuo","year":"2011","journal-title":"Retina"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajo.2008.07.017","article-title":"Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results","volume":"147","author":"Ikuno","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1111\/j.1755-3768.2010.02070.x","article-title":"Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization","volume":"90","author":"Ruiz-Moreno","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1111\/aos.14527","article-title":"Prevalence, risk factors and impact of posterior staphyloma diagnosed from wide-field optical coherence tomography in Singapore adults with high myopia","volume":"99","author":"Zheng","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jcjo.2011.12.009","article-title":"Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results","volume":"47","author":"Peiretti","year":"2012","journal-title":"Can J Ophthalmol"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ophtha.2009.11.003","article-title":"Long-term pattern of progression of myopic maculopathy: a natural history study","volume":"117","author":"Hayashi","year":"2010","journal-title":"Ophthalmology"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ajo.2008.07.022","article-title":"Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results","volume":"147","author":"Gharbiya","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000485112","article-title":"Nine-year outcome of ranibizumab monotherapy for choroidal neovascularization secondary to pathologic myopia","volume":"239","author":"Pastore","year":"2018","journal-title":"Ophthalmologica"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1097\/IAE.0000000000001453","article-title":"Five-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:05:57Z","timestamp":1749143157000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003675","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,16]]}}}